Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialMathias Rummel, Wolfram Brugger, Martina Stauch et al.|The Lancet|2013Cited by 1.5k
Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary HypertensionKhodr Tello, Manuel J. Richter, Jun Wan et al.|Circulation Cardiovascular Imaging|2019Cited by 596
Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic OverloadKhodr Tello, Manuel J. Richter, Antonia Dalmer et al.|Circulation Heart Failure|2019Cited by 262
Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).Mathias Rummel, Wolfram Brugger, N. Niederle et al.|Blood|2009Cited by 157
Evaluation and Prognostic Relevance of Right Ventricular–Arterial Coupling in Pulmonary HypertensionManuel J. Richter, Khodr Tello, Dana C. Peters et al.|American Journal of Respiratory and Critical Care Medicine|2019Cited by 136